The antithrombotic efficacy of the GP IIb/IIIa antagonist SR121787 is potentiated by antithrombin-dependent factor Xa inhibition without an increase in the bleeding risk in the rabbit

Journal of Cardiovascular Pharmacology

Volumn 33, Issue 4, 1999, Pages 573-579

  Bernat, A ^a   Savi, P ^a   Lale, A ^a   Hoffmann, P ^a   Herbert, J M ^a  

^a SANOFI   (France)

Author keywords

Factor Xa; GP IIb IIIa; Pentasaccharide; SR121787

Indexed keywords

3 [[4 [4 [AMINO(ETHOXYCARBONYLIMINO)METHYL]PHENYL] 2 THIAZOLYL](1 ETHOXYCARBONYLMETHYL 4 PIPERIDINYL)AMINO]PROPIONIC ACID ETHYL ESTER; BLOOD CLOTTING FACTOR 10A INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BLEEDING; CAROTID ARTERY THROMBOSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT; RISK; THROMBOCYTE AGGREGATION;

ANIMALS; ANTICOAGULANTS; ANTITHROMBINS; BENZYLAMINES; CAROTID ARTERIES; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FACTOR XA; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN; MALE; OLIGOSACCHARIDES; PIPERIDINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RABBITS; THIAZOLES;

EID: 0032957249     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199904000-00009     Document Type: Article

References (37)

1. Verstraete M. Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. Drugs 1990;40:498-530.
2. Verstraete M, Zoldheyi P. Novel antithrombotic drugs in development. Drugs 1995;49:856-84.
3. Paques EP, Römisch J. Comparative study on the in vivo effectiveness of antithrombotic agents. Thromb Res 1991;64:11-21.
4. Berry C, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb Haemost 1994;72:381-6.
5. Freund M, Cazenave JP, Courtney M, et al. Inhibition by recombinant hirudins of experimental venous thrombosis and disseminated intravascular coagulation induced by tissue factor in rats. Thromb Haemost 1990;63:187-92.
6. Agnelli G, Pascucci C, Cosni B, Nenci GG. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits. Thromb Haemost 1990;63:204-7.
7. Shetler TJ, Crowe VG, Bailey BD, Jackson CV. Antithrombotic assessment of the effects of combination therapy with the anticoagulants efegatran and heparin and the glycoprotein IIb-IIIa platelet receptor antagonist 7E3 in a canine model of coronary artery thrombosis. Circulation 1996;94:1719-25.
8. Lormeau JC, Hérault JP. The effect of the synthetic pentasaccharide SR90107/ORG31540/ORG 31540 on thrombin generation ex vivo is uniquely due to ATIII-mediated neutralization of factor Xa. Thromb Haemost 1995;74:1474-7.
9. Herbert JM, Petitou M, Lormeau JC, et al. SR90107/ORG31540A/Org 31540: a novel anti-factor Xa antithrombotic agent. Cardiovasc Drug Rev 1997;15:1-26.
10. Vogel GM, Meuleman DG, Bourgondiën FG, Hobbelen M. Comparison of two experimental thrombosis models in rats: effect of four glycosaminoglycans. Thromb Res 1989;54:399-410.
11. Hobbelen PMJ, Van Dinther TG, Vogel GMT, et al. Pharmacological profile of the chemically synthesized antithrombin III binding fragment of heparin (pentasaccharide) in rats. Thromb Haemost 1990;63:265-72.
12. Walenga JM, Fareed J, Petitou M, Samama M, Lormeau JC, Choay J. Intravenous antithrombotic activity of a synthetic heparin pentasaccharide in a human serum induced stasis thrombosis model. Thromb Res 1986;43:243-8.
13. Walenga JM, Petitou M, Lormeau JC, Samama M, Fareed J, Choay J. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges. Thromb Res 1987;46:187-98.
14. Walenga JM, Petitou M, Samama M, Fareed J, Choay J. Importance of a 3-O-sulphale group in a heparin pentasaccharide for antithrombotic activity. Thromb Res 1988;52:553-63.
15. Cadroy Y, Hansson SR, Harker LA. Antithrombotic effects of synthetic pentasaccharide with high affinity for plasma antithrombin III in non-human primates. Thromb Haemost 1993;70:631-5.
16. Coller BS. GPIIb/IIIa antagonists : pathophysiologic and therapeutic insights from studies of c7E3 Fab. Thromb Haemost 1997;78:730-5.
17. Topol EJ. Targeted approaches to thrombus inhibition: an end to the shotgun approach. Clin Cardiol 1997;20(suppl I):I-22-6.
18. Frederick LG, Suleymanov OD, King LW, Salyers AK, Nicholson NS, Feigen LP. The protective dose of the potent GPIIb/IIIa antagonist SC-54701A is reduced when used in combination with aspirin and heparin in a canine model of coronary artery thrombosis. Circulation 1996;93:129-34.
19. Savi P, Badorc A, Bordes MF, et al. SR121787, a new orally active fibrinogen receptor antagonist. Thromb Haemost 1998;80:469-76.
20. Hoffmann P, Bernat A, Savi P, Herbert JM. Antiplatelet and antithrombotic efficacy of SR121787: a nonpeptide orally active GP IIb/IIIa antagonist, in rabbits: comparison with clopidogrel and aspirin. J Cardiovasc Pharmacol 1997;30:360-6.
21. Hérault JP, Peyrou V, Savi P, Bernat A, Herbert JM. Effect of SR121566A: a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo. Thromb Haemost 1998;79:383-8.
22. Hoffmann P, Bernat A, Savi P, Herbert JM. Prevention of thrombosis and enhancement of thrombolysis in rabbits by SR121787: a glycoprotein II/III antagonist. J Pharmacol Exp Ther (in press).
23. Hladovec I. Experimental arterial thrombosis in rats with continuous registration. Thromb Diathes Haemorrh 1971;26:407-10.
24. Herbert JM, Hérault JP, Bernat A, et al. Biochemical and pharmacological properties of SANORG 32701: comparison with the synthetic pentasaccharide (SR90107/ORG31540) and standard heparin. Circ Res 1996;79:590-600.
25. Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927-9.
26. Herbert JM, Bernat A, Dol F, Hérault JP, Crépon B, Lormeau JC. DX 9065A: a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies. J Pharmacol Exp Ther 1996;276:1030-8.
27. Théroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988;319:1105-11.
28. Topol E. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
29. ISIS-3 Investigators. ISIS-3: a randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,229 cases of suspected acute myocardial infarction. Lancet 1993;339:754-70.
30. Landau C, Lange RA, Hillis LD. Percutaneous transluminal coronary angioplasty. N Engl J Med 1994;330:981-93.
31. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:242-50, 310-8.
32. Davies MJ. A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation 1990;82(suppl II):II-38-46.
33. de Feyter PJ. The benefits and risks of coronary intervention: balancing the equation. Clin Cardiol 1997;20(suppl I):I-14-21.
34. Herbert JM, Bernat A, Dol F, Hérault JP, Crépon B, Lormeau JC. DX 9065A: a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies. J Pharmacol Exp Ther 1996;276:1030-8.
35. Sato K, Kawasaki T, Taniuchi Y, Hirayama F, Koshio H, Matsumoto Y. YM-60828: a novel factor Xa inhibitor: separation of its antithrombotic effects from its prolongation of bleeding time. Eur J Pharmacol 1997;339:141-6.
36. Berndt MC, Gregory C, Dowden G, Castaldi PA. Thrombin interaction with platelet membrane proteins. Ann NY Acad Sci 1986;485:374.
37. Higgins DL, Lewis SD, Shafer JA. Steady state kinetic parameters for the thrombin catalyzed conversion of human fibrinogen to fibrin. J Biol Chem 1983;258:9276.